Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mitochondrial DNA regulates mitochondrial function which is altered in both idiopathic and familial forms of Parkinson's disease. To investigate whether these two disease forms exhibit an altered regulation of mitochondrial DNA we measured cell free mitochondrial DNA content in cerebrospinal fluid (CSF) from idiopathic and LRRK2-related Parkinson's disease patients. The concentration of mitochondrial DNA was measured using a digital droplet polymerase chain reaction technique in a total of 98 CSF samples from a cohort of subjects including: 20 LRRK2(G2019S) mutation carriers with Parkinson's disease, 26 asymptomatic LRRK2(G2019S) mutation carriers, 31 patients with idiopathic Parkinson's disease and 21 first-degree relatives of LRRK2 Parkinson's disease patients without the mutation. Here we report that LRRK2(G2019S) mutation carriers with Parkinson's disease exhibit a high concentration of mitochondrial DNA in CSF compared with asymptomatic LRRK2(G2019S) mutation carriers and with idiopathic Parkinson's disease patients. In addition, idiopathic, but not LRRK2 Parkinson's disease is associated with low CSF concentration of α-synuclein. These results show that high mitochondrial DNA content in CSF distinguishes idiopathic from LRRK2-related Parkinson's disease suggesting that different biochemical pathways underlie neurodegeneration in these two disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Transcellular degradation of axonal mitochondria
Davis, C.-H. O., Kim, K.-Y., Bushong, E. A., Mills, E. A., Boassa, D., Shih, T., Kinebuchi, M., Phan, S., Zhou, Y., Bihlmeyer, N. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404651111 · Cited by 673 · cited 1×
“One possibility is that mtDNA is released from cells into CSF in a physiological process of mitochondrial quality control, known as trans-mitophagy, that targets mitochondria for trans-cellular mitochondrial degradation (Davis et al., 2014;Davis & Marsh-Armstrong, 2014).”
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524 · cited 3×
“Actually, like in the case of monogenic forms of hereditary Parkinson’s disease, there is extensive evidence showing that mitochondrial function is also altered in idiopathic Parkinson’s disease (Ryan et al., 2015;Johri & Beal, 2012).”
InfluentialRamonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405 · cited 1×
“Actually, studies in cultured neurons, neuroblastoma cells and transgenic mice have shown that the LRRK2 G2019S mutation disrupts mitochondrial dynamics and enhances mitophagy (Wang et al., 2012;Niu et al., 2012;Su & Qi, 2013;Cherra, III et al., 2013;Ramonet et al., 2011).”
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo
Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001905 · Cited by 131 · cited 1×
“…disease manifesting and non-manifesting LRRK2 G2019S mutation carriers is not a consequence of altered mitochondrial function because mitochondrial dysfunction occurs in LRRK2 G2019S mutation carriers independently of whether they manifest Parkinson’s disease or not (Mortiboys et al., 2015).”
Cited by
ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders
Gambardella, S., Limanaqi, F., Ferese, R., Biagioni, F., Campopiano, R., Centonze, D., & Fornai, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01064 · Cited by 141
“G2019S mutation in LRRK2 (48), which affects mitochondrial function/dynamics by slowing down mitophagy (49–51).”
BackgroundInfluentialMaatouk, L., Compagnion, A.-C., Sauvage, M.-A. C.-D., Bemelmans, A.-P., Leclere-Turbant, S., Cirotteau, V., Tohme, M., Beke, A., Trichet, M., Bazin, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04569-y · Cited by 95
Urinary Biomarkers for Neurodegenerative Diseases
Seol, W., Kim, H., & Son, I. (2020) · Experimental Neurobiology · doi:10.5607/en20042 · Cited by 61
“If the intact urine is used for analysis without any further process, the used volume itself can function as a normalizer [71, 72].”
BackgroundMethodRole of mtDNA disturbances in the pathogenesis of Alzheimer’s and Parkinson’s disease
Antonyová, V., Kejík, Z., Brogyányi, T., Kaplánek, R., Pajková, M., Talianová, V., Hromádka, R., Masařík, M., Sýkora, D., Mikšátková, L., et al. (2020) · DNA Repair · doi:10.1016/j.dnarep.2020.102871 · Cited by 45
Metadata
- Authors
- Podlesniy, P., Vilas, D., Taylor, P., Shaw, L. M., Tolosa, E., & Trullas, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 94
- Pages
- 10-17
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2408902173
- Cited by
- 43
- References
- 5
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.